Innoviva, Inc. (INVA)
Market Cap | 1.03B |
Revenue (ttm) | 311.59M |
Net Income (ttm) | 181.39M |
Shares Out | 62.44M |
EPS (ttm) | 2.21 |
PE Ratio | 7.47 |
Forward PE | 24.89 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 298,757 |
Open | 16.46 |
Previous Close | 16.50 |
Day's Range | 16.37 - 16.61 |
52-Week Range | 12.22 - 16.86 |
Beta | 0.58 |
Analysts | Buy |
Price Target | n/a |
Earnings Date | Jul 31, 2024 |
About INVA
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic o... [Read more]
Financial Performance
In 2023, Innoviva's revenue was $310.46 million, a decrease of -6.30% compared to the previous year's $331.34 million. Earnings were $179.72 million, a decrease of -15.99%.
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/q/s/drugs34-2485327.jpg)
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
Cantor Fitzgerald has initiated coverage on Innoviva, Inc. INVA, citing the company's unique business model centered around royalties and healthcare assets.
![](https://cdn.snapi.dev/images/v1/w/l/conf20-2458579.jpg)
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
![](https://cdn.snapi.dev/images/v1/c/e/press4-2421689.jpg)
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
![](https://cdn.snapi.dev/images/v1/w/z/press20-2417574.jpg)
Innoviva to Participate in the BofA Securities Health Care Conference
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
![](https://cdn.snapi.dev/images/v1/p/5/press1-2387614.jpg)
Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that positive results from the Phase 3 oral zoliflodacin trial wi...
![](https://cdn.snapi.dev/images/v1/5/n/press19-2307305.jpg)
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
Proceeds to be used to continue to advance rigorously designed clinical trials of Armata's high purity phage-based therapeutic candidates LOS ANGELES , March 4, 2024 /PRNewswire/ -- Armata Pharmaceuti...
![](https://cdn.snapi.dev/images/v1/e/r/press9-2302272.jpg)
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
![](https://cdn.snapi.dev/images/v1/s/7/im-823645size1777777777777778w-2299457.jpg)
10 stocks you can bet on being inflation-proof
New research shows that “quality” stocks — companies with high operating profitability but which are out of favor on Wall Street — are the type of stocks most likely to do well if inflation heats up. ...
![](https://cdn.snapi.dev/images/v1/l/y/press4-2134372.jpg)
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reporte...
![](https://cdn.snapi.dev/images/v1/6/c/press1-2134194.jpg)
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
GENEVA & WALTHAM, Mass.--(BUSINESS WIRE)--The Global Antibiotic Research & Development Partnership (GARDP), in collaboration with Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasda...
![](https://cdn.snapi.dev/images/v1/c/8/press8-2098669.jpg)
Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), announced today plans to present an oral abstract and four poster sessions from their p...
![](https://cdn.snapi.dev/images/v1/o/u/conf12-2069105.jpg)
Innoviva to Participate in the Cantor Global Healthcare Conference
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Pavel Rai...
![](https://cdn.snapi.dev/images/v1/b/d/press10-2067139.jpg)
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that XACDURO® (sulbactam for injection; durlobactam for injection) is n...
![](https://cdn.snapi.dev/images/v1/j/k/press18-2038394.jpg)
Innoviva Appoints Stephen Basso as Chief Financial Officer
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announ...
![](https://cdn.snapi.dev/images/v1/k/x/press6-2002527.jpg)
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reporte...
![](https://cdn.snapi.dev/images/v1/p/c/press15-1970318.jpg)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Innoviva, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK , July 13, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim...
![](https://cdn.snapi.dev/images/v1/t/k/press2-1965772.jpg)
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
Signs new $25 million credit agreement and extension of existing secured convertible credit agreement Appoints world‐renowned healthcare leader Dr. Deborah L. Birx as Chief Executive Officer MARINA DE...
![](https://cdn.snapi.dev/images/v1/v/t/conf8-1923665.jpg)
Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Pavel Rai...
![](https://cdn.snapi.dev/images/v1/i/p/biotech9-1904547.jpg)
FDA approves Innoviva's bacterial pneumonia treatment
The Food and Drug Administration said Tuesday that it approved Innoviva's Xacduro pneumonia treatment, which fights the Acinetobacter bacteria.
![](https://cdn.snapi.dev/images/v1/b/9/press13-1904455.jpg)
Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that the U.S. Food and Drug Administration (FDA) approved XACDURO® (sul...
![](https://cdn.snapi.dev/images/v1/t/r/press8-1886687.jpg)
Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA) focused on delivering innovative therapies in critical care and infectious disease, toda...
![](https://cdn.snapi.dev/images/v1/w/k/press6-1880827.jpg)
Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or “the Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reporte...
![](https://cdn.snapi.dev/images/v1/r/g/press4-1861740.jpg)
Innoviva Announces Retirement of Board Chairman
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) and George Bickerstaff, III, Chairman of the Board of Directors of the Company (the “Board”) today ann...
![](https://cdn.snapi.dev/images/v1/q/z/press13-1840495.jpg)
Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (Innoviva), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that the U.S.
![](https://cdn.snapi.dev/images/v1/b/m/press11-1839599.jpg)
Innoviva Stock Trading Halted Today
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (Innoviva), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Nasdaq has ...